-
Document de presse | 2021.10.26
The intranasal lentiviral vaccine candidate (Lenti-S) protects brain and lung in a pre-clinical animal model
The SARS-CoV-2 virus, responsible for the COVID-19 pandemic, primarily targets the respiratory tract, but its ability to infect cells of the nervous system has also been largely reported. Indeed, the expression of the receptor of this virus, the Angiotensin Converting Enzyme 2 (ACE2), by neuronal and glial cells makes the brain susceptible to SARS-CoV-2. Moreover, neurological manifestations are...
-
Document de presse | 2021.10.11
SARS-CoV-2 Alpha, Beta and Delta variants display enhanced viral fusion properties compared to ancestral strains
In a new study published in EMBO Journal on October 2, 2021, scientists from the Institut Pasteur, the CNRS, Université de Paris, the Vaccine Research Institute and Sorbonne University examined the fusion mechanisms of different SARS-CoV-2 variants: Alpha (initially identified in the United Kingdom), Beta (initially identified in South Africa) and Delta (initially identified in India). The Delta...
-
Document de presse | 2021.09.27
SARS-CoV-2: different immune responses observed in nasal mucosa and blood
The clinical manifestations of SARS-CoV-2 infection vary from one individual to the next, and much remains unknown about the mechanisms underpinning this variability. Since the nasal mucosa is one of the first entry points of the virus, scientists from the Institut Pasteur and Inserm, in collaboration with Cochin AP-HP Hospital, analyzed in parallel the immune responses in the nasal mucosa and in...
-
News | 2021.11.10
COVID-19: Kamala Harris, Vice President of the United States, salutes the Institut Pasteur's response in tackling the pandemic
As part of her trip to France for the fourth Paris Peace Forum – which includes three round tables on the challenges raised by the COVID-19 pandemic –, Kamala Harris, Vice President of the United States, visited the Institut Pasteur on November 9, 2021. She met several of the Institut Pasteur's scientists and saluted the unprecedented response of the Institut Pasteur's scientific community in...
-
Document de presse | 2021.11.18
Covid-19: Systematic review of the clinical and immunological efficacy of vaccines in immunocompromised people
The team from the Cochin-Pasteur Clinical Investigation Center of Vaccinology at Cochin AP-HP Hospital, Inserm and the University of Paris, coordinated by Prof. Odile Launay, carried out a systematic review of the literature on immunogenicity and efficacy of Covid-19 vaccines in immunocompromised individuals. It concluded that there is a risk of low immunogenicity of Covid-19 vaccines among...
-
Document de presse | 2021.11.26
ComCor study: new results on places of infection with SARS-CoV-2 and analysis of the efficacy of messenger RNA vaccines against the Delta variant
From May 23 to August 13, 2021, the Institut Pasteur, in partnership with the French National Health Insurance Fund (CNAM), Santé publique France and the Ipsos institute, conducted the fourth part of the ComCor epidemiological study on circumstances and places of infection with the SARS-CoV-2 virus in France. The aim of the study was to identify the socio-demographic factors, places visited and...
-
News | 2021.11.30
Composition of the gut microbiota modulates the severity of Clostridioides difficile infection
During infection, the pathogenic bacterium interacts closely with the bacteria in the gut. They may have to share resources, thereby limiting infection with the pathogen, or alternatively the pathogen may draw benefits from this cohabitation for its infectious strategy.Infection with Clostridioides difficile is the main cause of infectious diarrhea in hospitals and long-term care facilities....
-
Document de presse | 2021.12.01
Virus related to SARS-CoV-2 found in bats in Cambodia
What are the origins of SARS-CoV-2? This is the world’s most pressing scientific puzzle. Its pieces scattered throughout the world are currently being sought out by scientists. Their goal: to track down the culprit for the largest health crisis to hit the globe in the past century. Scientists at the Institut Pasteur in Paris and the Institut Pasteur du Cambodge have identified a coronavirus in...
-
Document de presse | 2021.12.06
Chronic obstructive pulmonary disease: a genetic mutation confirmed as predisposing factor
In 2019, the WHO positioned chronic obstructive pulmonary disease (COPD) third in the global ranking of causes of death. However, some mechanisms of this debilitating chronic respiratory disease are yet to be identified. Against this backdrop, scientists at the Institut Pasteur, Université de Paris, CNRS, Inserm, University of Reims Champagne-Ardenne, Reims University Hospital and the Institut...
-
News | 2021.12.14
2022: the bicentenary of Louis Pasteur's birth
Louis Pasteur was born on December 27, 1822. He was an international figure in scientific and medical research and the founder of the Institut Pasteur (Paris) in 1887. Louis Pasteur was a precursor of a certain way of conducting research, deeply concerned with its goals, both humanistic and universal, and the need to train and transmit this approach and these values to future generations. Today,...
